EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Relationships of genetic polymorphisms in CYP3A5 and UGT1A1 with plasma bictegravir concentrations and subjective adverse symptoms in Japanese patients with HIV-1 infection

Hiroki Yagura, Ayumi Hisari, Takao Nakauchi, Ayano Fujiwara, Kazuyuki Hirota, Takashi Ueji, Yasuharu Nishida, Tomoko Uehira, Takuma Shirasaka, Jun A Komano, Dai Watanabe

Journal of Antimicrobial Chemotherapy · 2026-10-06 · 81 (11)

DOI: 10.1093/jac/dkag378 ↗
AbstractBibliografische Angaben

Abstract

Abstract Objectives Bictegravir is primarily metabolized by cytochrome P450 (CYP) 3A and UDP-glucuronosyltransferase (UGT) 1A1, both of which show genetic polymorphisms. We investigated the relationships of CYP3A5 and UGT1A1 genetic polymorphisms with plasma BIC concentrations and the occurrence of subjective adverse symptoms. Patients and methods The presence of the CYP3A5*3, UGT1A1*6 and UGT1A1*28 alleles was determined in 110 patients. Blood samples were collected at a single time point from each patient on or after Day 14 of administration for the measurement of plasma bictegravir concentration. Associations between these genetic variants, plasma bictegravir concentrations and subjective adverse symptoms within 24 weeks after the initiation of bictegravir were analysed. Results Allele frequencies of CYP3A5*3, UGT1A1*6 and UGT1A1*28 were 78%, 13% and 14%, respectively. Linear regression analysis demonstrated higher plasma bictegravir concentrations in patients with homozygous CYP3A5*3 variants and in those with homozygous or compound heterozygous UGT1A1 variants (*6/*6, *28/*28 or *6/*28). Trough plasma bictegravir concentrations (n = 65, 20–27 h post-dose) were 18% and 69% higher, respectively, in these groups (P = 0.041; P = 0.017). Multiple regression analysis showed that these genetic polymorphisms independently and significantly contributed to variability in plasma bictegravir concentrations. Subjective adverse symptoms were observed in 62 patients (56%), with increased appetite being the most frequent symptom (23 patients, 21%). Homozygous UGT1A1*6, compound heterozygous *6/*28 and homozygous *28 variants independently correlated with the occurrence of increased appetite (P = 0.0303). Conclusions UGT1A1 genetic polymorphisms were considered to independently affect plasma bictegravir exposure, whereas CYP3A5 might have a greater impact on BIC exposure when combined with UGT1A1 genetic variants. These findings suggest the need to assess both CYP3A5 and UGT1A1 genetic polymorphisms when evaluating the effects of drug-metabolizing enzymes on bictegravir concentrations.

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →